Financial Data and Key Metrics Changes - The company reported revenue of 66millionforQ3FY24,representingan86.5 million, or adjusted loss per share of 0.16,comparedtoanadjustednetlossof5.4 million or adjusted loss per share of 0.14inthesamequarterlastyear[26]−GAAPnetlossforQ3FY24was190.4 million, including a goodwill impairment charge of 159.5million[27]BusinessLineDataandKeyMetricsChanges−Medtechrevenuewas25.7 million, a 12.6% year-over-year increase, while med device revenue was 40.3million,growing5.211.8 million in revenue during Q3, growing 14.7% year-over-year [21] - NanoKnife disposable revenue increased 19.8% year-over-year, with capital sales growing 230.9% [22] Market Data and Key Metrics Changes - International business grew approximately 21% year-over-year, with med tech growing 53% and med device growing 7% [16] - The company expects to initiate a limited launch of AlphaVac for pulmonary embolism treatment by the end of Q4 FY24, with a full launch scheduled for Q1 FY25 [12][13] Company Strategy and Development Direction - The company is focused on optimizing its portfolio, having divested its PICC and midline product portfolios for up to 45million,with30 million received in Q3 [17] - The transition to a fully outsourced manufacturing model is underway, expected to generate approximately 15millioninannualizedsavingsstartinginFY26[18][24]−Thecompanyaimstodrivegrowthfromkeymedtechplatformswhileexpandingmarginsandmovingtowardsprofitability[9]Management′sCommentsonOperatingEnvironmentandFutureOutlook−Managementexpressedconfidenceinthegrowthstrategy,highlightingtheFDAclearanceforAlphaVacasasignificantmilestone[12]−ThecompanyanticipatesFY24revenueintherangeof270 million to 275million,reflectingtheimpactofrecentdivestitures[32]−Managementnotedthattherearenosignificantmarketchangesaffectingguidance,maintainingaconsistentoutlookdespiteoperationaltransitions[42]OtherImportantInformation−Thecompanyhaszerodebtcomparedto50 million a year ago, significantly strengthening its balance sheet [28][30] - A settlement agreement with BD Bard was reached, resolving over a decade of IP litigation, providing clarity and allowing the company to focus on growth [31] Q&A Session Summary Question: When will data from the APEX trial be available? - Management indicated that data will be released at upcoming trade shows and through publications from principal investigators [36] Question: What are the rollout plans for AlphaVac in PE? - The company has prepared its sales force and will conduct a limited market release followed by a larger launch [48] Question: Will there be any changes in guidance due to recent divestitures? - Management confirmed that guidance remains consistent, reflecting the divestiture's impact without significant market changes [42] Question: What is the pricing strategy for AlphaVac? - The expected price for AlphaVac is around $9,000 [60] Question: How is the NanoKnife performing and when will PRESERVE data be available? - The NanoKnife is seeing strong growth, particularly in prostate treatments, with data from the PRESERVE study expected to be published following the 12-month follow-up [62]